ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TCRT vs ENSC // NET PROFIT MARGIN

Alaunos Therapeutics Inc. (NASDAQ) VS. Ensysce Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: TCRT 2 — ENSC 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TCRT VS. ENSC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TCRT ENSC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin ACTIVE -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -50.00% -2.80% -47.20 ENSC /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 TCRT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.1 41.4 +8.70 TCRT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $8.1M $8.2M -$140.8K ENSC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TCRT REV ENSC REV TCRT GROSS % ENSC GROSS % TCRT FCF ENSC FCF
FY 2025 $5.0K $5.1M — — -$3.0M -$7.9M
FY 2024 $10.0K $5.2M — — -$5.0M -$7.5M
FY 2023 $5.0K $2.2M — — -$30.1M -$10.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TCRT // BETA —
ENSC // BETA —